Dear Sir, Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, please note that the Board in their meeting held on ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Omkar Pharmachem Ltd held a board meeting on 14 February 2026 and approved two items: (1) Unaudited Financial Results for Q3 and nine months ended 31 December 2025, and (2) noted the completion of tenure of Mr. Janak Raj Sharma as Independent Director, who ceased to hold office from close of business on 12 February 2026 after completing two consecutive 5-year terms. For Q3 FY26, the company reported total income of Rs. 10.50 lakhs and profit after tax of Rs. 2.95 lakhs, down from Rs. 13.50 lakhs and Rs. 8.49 lakhs respectively in the same quarter last year. For the nine-month period, profit after tax fell sharply to Rs. 10.68 lakhs from Rs. 22.24 lakhs in the previous year, a roughly 52% decline. Net sales remain nil across all periods, with income primarily from other operating sources.
The director's exit is a routine, regulatory completion of his maximum allowable tenure as an Independent Director — not a governance red flag. However, the sharp drop in nine-month profits and continued zero revenue from core operations suggest weak business activity, which is a negative signal for shareholders.